Athersys to Host Third Quarter Financial Results Call

October 9, 2018

CLEVELAND, Ohio, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) will release its third quarter 2018 financial results at approximately 4:00 p.m. Eastern Time on Tuesday, November 6th, 2018, and will host a conference call shortly thereafter at 4:30 p.m. Eastern Time to review the results. William (B.J.) Lehmann, President and Chief Operating Officer, and Laura Campbell, Senior Vice President of Finance, will host the call as follows:

Date November 6, 2018 ------------------------------- ---------------------------------------- Time 4:30 p.m. (Eastern Time) ------------------------------- ---------------------------------------- Telephone access: US and Canada (800) 273-1254 ------------------------------- ---------------------------------------- Telephone access: International (973) 638-3440 ------------------------------- ---------------------------------------- Access code 7396506 ------------------------------- ---------------------------------------- Live webcast www.athersys.com under Investors section ------------------------------- ----------------------------------------

A replay will be available for on-demand listening shortly after the completion of the call until 11:59 p.m. Eastern Time on November 20, 2018 at the aforementioned URL or by dialing (800) 585-8367 or (855) 859-2056 in the U.S. and Canada, or from abroad (404) 537-3406, and entering access code 7396506.

About Athersys

Athersys is an international biotechnology company engaged in the development of therapeutic products designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived “off-the-shelf” stem cell product, initially for disease indications in the neurological, cardiovascular, and inflammatory and immune disease areas, and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance MultiStem cell therapy toward commercialization. More information is available at www.athersys.com. Follow Athersys on Twitter at www.twitter.com/athersys.



William (B.J.) Lehmann President and Chief Operating Officer Tel: (216) 431-9900 bjlehmann@athersys.com

Karen Hunady Corporate Communications & Investor RelationsTel: (216) 431-9900 khunady@athersys.com

David Schull Russo Partners, LLCTel: (212) 845-4271 or (858) 717-2310 David.schull@russopartnersllc.com

Update hourly